Young Brian Y, Gill Jagbir, Huang Edmund, Takemoto Steven K, Anastasi Bishoy, Shah Tariq, Bunnapradist Suphamai
David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.
Clin J Am Soc Nephrol. 2009 Apr;4(4):845-52. doi: 10.2215/CJN.02250508. Epub 2009 Feb 6.
Transplant options for type I diabetics with end-stage renal disease include simultaneous pancreas-kidney (SPKT), living donor kidney (LDKT), and deceased donor kidney transplant (DDKT). It is unclear whether SPKT offers a survival benefit over LDKT in the current era of transplantation. The authors compared outcomes of kidney transplant recipients with type I diabetes using data from the Organ Procurement and Transplant Network/United Network for Organ Sharing.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Adult (age 20 to 59) type I diabetics who received a solitary first-time kidney transplant between 2000 and 2007 were studied. Outcomes included overall kidney graft and patient survival. Multivariate analysis was performed using a stepwise Cox proportional hazards model.
Kidney graft survival was better for recipients of LDKT compared with SPKT (P = 0.008), although patient survival was similar (P = 0.346). On multivariate analysis, LDKT was associated with lower adjusted risks over 72 mo follow-up of kidney graft failure (HR 0.71; 95% CI 0.61 to 0.83) and patient death (HR 0.78; 95% CI 0.65 to 0.94) versus SPKT. Compared with DDKT, SPKT had superior unadjusted kidney graft and patient survival, partly due to favorable SPKT donor and recipient factors.
Despite more transplants from older donors and among older recipients, LDKT was associated with superior outcomes compared with SPKT and was coupled with the least wait time and dialysis exposure. LDKT utilization should be considered in all type I diabetics with an available living donor, particularly given the challenges of ongoing organ shortage.
终末期肾病的I型糖尿病患者的移植选择包括胰肾联合移植(SPKT)、活体供肾移植(LDKT)和尸体供肾移植(DDKT)。在当前移植时代,SPKT是否比LDKT具有生存优势尚不清楚。作者使用器官获取与移植网络/器官共享联合网络的数据比较了I型糖尿病肾移植受者的结局。
设计、地点、参与者和测量:研究了2000年至2007年间接受首次单独肾移植的成年(20至59岁)I型糖尿病患者。结局包括总体肾移植和患者生存情况。使用逐步Cox比例风险模型进行多变量分析。
与SPKT相比,LDKT受者的肾移植生存率更高(P = 0.008),尽管患者生存率相似(P = 0.346)。在多变量分析中,与SPKT相比,LDKT在72个月的随访中与较低的肾移植失败调整风险(HR 0.71;95% CI 0.61至0.83)和患者死亡调整风险(HR 0.78;95% CI 0.65至0.94)相关。与DDKT相比,SPKT的未调整肾移植和患者生存率更高,部分原因是SPKT供体和受体因素有利。
尽管来自老年供体和老年受者的移植更多,但与SPKT相比,LDKT的结局更好,并且等待时间和透析暴露时间最短。对于所有有活体供体的I型糖尿病患者,应考虑使用LDKT,特别是考虑到持续的器官短缺挑战。